VIA The National Hemophilia Foundation:
CSL Behring has announced that due to patients transitioning from plasma-derived to recombinant products, it has been difficult to sustain the production and distribution of Antihemophilic Factor Monoclate-P® Factor VIII:C Pasteurized Monoclonal Antibody Purified. Therefore production of Monoclate-P® will be discontinued, and CSL Behring estimates that existing supplies will only be available until December 2018.
If you are currently using Monoclate-P®, please contact your physician or hemophilia treatment center to learn about other options that are available to you for treatment.
